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Introduction
Therapeutic approaches using ex vivo immunological modification of malignant cells or bone marrow purging systems have not yet been widely investigated in hematological malignancies. One of the prerequisites to these applications is a safe vector that can achieve highefficiency ex vivo gene transfer in leukemic cells, without major cytotoxicity. As nonviral systems remain poorly efficient, different viruses have been tested for their ability to transduce leukemic cells. Retroviral vectors are able to transduce a wide range of hematopoietic cells, but they require proliferating cells, and their large-scale production is labor intensive. Adenoviruses can introduce foreign genes in nonreplicating cells, generally do not integrate into the genome, can be produced at a high titer, and have been widely used as vectors in various cell types. However, their ability to transduce hematopoietic cells remains controversial. Recent reports have described successful gene transfer with adenoviral vectors in dendritic or CD34-positive cells but other groups have reported low transfer efficiency in bone marrow cells. [1] [2] [3] [4] [5] [6] [7] Adenoviruses can achieve significant gene transfer in myeloma, chronic myeloid leukemia (CML) and activated chronic lymphoid leukemia (CLL) cells, and we have previously reported the poor ability of adenovirus vectors to transduce acute myeloid leukemia (AML) cells. [8] [9] [10] Adenoviruses infect host cells after viral attachment mediated by the knob domain of the fiber protein and two distinct cellular receptors, the ␣2 domain of the major histocompatibility complex (MHC) class I, and the recently described Coxsackie virus-Ad receptor (CAR). [11] [12] [13] However, this receptor is weakly expressed on peripheral blood cells. 13 Additionally, hematological cells, except CLL cells activated with CD154 or IL-4 and monocytes activated with GM-CSF or M-CSF, express low levels of ␣ v ␤ 3 and ␣ v ␤ 5 integrins, which mediate adenovirus internalization via an RGD motif by binding to the adenoviral penton base. 14, 15 Different strategies to expand adenovirus tropism to many tissues have been recently developed. A recent report showed that adenovirus gene delivery to dendritic cells, which express ␣ v integrins, was greatly enhanced by combining liposomes with the adenoviruses, suggesting that the poor efficiency of adenovirus gene delivery in hematopoietic cells can be overcome by enhancement of virus internalization. 16 Another strategy is the retargeting of viral attachment via cellular receptors other than class I MHC or CAR. Wickham et al 17, 18 described a new adenoviral vector AdZ.F(pK7) containing a modified fiber protein where polylysine had been added to the C-terminal end of the fiber. This vector, through binding of polylysines to heparan sulfate containing receptors could increase virus adsorption and gene transfer efficiency in cell types expressing low levels of adenovirus receptors. As hematopoietic stem cells express heparan sulfate containing receptors, we investigated the ability of AdZ.F(pK7) vector to achieve efficient gene transfer in primary cultured fresh AML blast cells.
Results

Gene delivery in cell lines
AdZ.F and AdZ.F(pK7) transduced HeLa cells with similar efficacy, confirming a previous report which showed that equal particle comparisons give equivalent transduction of cell lines which express high levels of CAR. 17 The K562 cell line, known to be permissive for adenovirus infection was more efficiently transduced by AdZ.F(pK7) compared with AdZ.F (P = 0.01, Student's t test) ( Figure  1 ). However, AdZ.F transduced the HL60 cell line slightly more efficiently than AdZ.F(pK7) but the difference was not significant (P = 0.19, Student's t test).
Gene delivery in AML blast samples at growing virus doses The incubation of 10 AML blast samples at different physical virus particle doses of AdZ.F or AdZ.F(pK7) showed that AdZ.F(pK7) transduced cells at considerably higher efficiency (Mann-Whitney rank test, P Ͻ 0.001) (Figure 2a) . At AdZ.F(pK7) virus doses greater than 8400 physical particles per cell (equivalent to 100 plaque forming units (p.f.u.) per cell), transduction efficiency did not increase, and this dose was chosen for further experiments. Differences in active particle doses used with AdZ.F and AdZ.F(pK7) could not account for the greater efficiency of AdZ.F(pK7) because less p.f.u. per cell of AdZ.F(pK7) than of the control AdZ.F were always used. Cytotoxicity measured 72 h after infection by blue dye exclusion assay was less than 5% at 8400 (100 p.f.u. per cell) and 16 800 (200 p.f.u. per cell) AdZ.F (pK7) physical particles per cell. ). The total number of cells increased between transduction and 3 days posttransduction in 15 cases, and remained stable in 10 cases, but these growth profiles had no influence on FDG test results. Cytotoxicity measured 72 h after transduction with both viruses was less than 5% for each sample.
Long-term transgene expression with AdZ.F(PK7) Gene expression was also sequentially measured after transduction in 10 samples, during 20 days: transgene expression became detectable 24 h after transduction with AdZ.F(pK7) or AdZ.F, and all AML samples transduced with AdZ.F(pK7) remained 90% positive for FDG test in flow cytometry at day 15, but only 1-5% of the cells remained positive when transduced with AdZ.F ( Figure 4 ). After day 15, a rapid decrease of cell viability occurred and primary culture of AML cells could not be maintained longer than 3 weeks.
Growth factor requirement for transduction of AML cells with AdZ.F(pK7)
Primary culture of AML blasts samples with growth factors showed a rapid increase of cell count between day 3 and day 6, after which primary cultures could be maintained for 2 weeks with minor changes of cell proliferation ( Figure 5b ). As shown in Figure 5a , growth factors (SCF, IL-3, GM-CSF) seemed to be required for transduction in AML samples tested with either AdZ.F(pK7) or AdZ.F (P = 0.02, Student's t test). Transductions without growth factors resulted in low numbers of FDG-positive cells, and a rapid decrease of cell viability.
Adenovirus competition experiments and enzymatic treatment Incubation of 10 AML blast samples and HL60 leukemic cell line with heparin resulted in a strong inhibition of gene delivery by AdZ.F(pK7) (P = 0.001, Student's t test), except in the HL60 cell line, and had no effect on AdZ.F ( Figure 6 ). As the polylysine tail of AdZ.F(pK7) could bind to many polyanions, we performed enzymatic digestion experiments. Preincubation of five AML samples with heparinase I and neuraminidase showed that enzymatic treatment with heparinase I dramatically reduced transduction efficiency with AdZ.F(pK7) but had no effect with AdZ.F (P = 0.01, Student's t test) ( Figure  7 ). Neuraminidase treatment did not affect transduction efficiency (P = 0.6, Student's t test). Heparinase I treatment of samples 7 and 8, which showed only minor differences of transduction by AdZ.F and AdZ.F(pK7), reduced AdZ.F(pK7) but not AdZ.F transduction efficiency. We also observed a moderate inhibition of AdZ.F(pK7) transduction efficiency with neuraminidase treatment (Figure 7 ). This suggested that AdZ.F(pK7) gene delivery in AML blasts was mediated mostly by heparan sulfates except in some samples where other negative charges could participate. bodies directed against the fiber covalently linked to a ligand, and addition to the knob domain of RGD sequences or polylysines. [19] [20] [21] [22] [23] [24] We have shown in this study that the control AdZ.F adenovirus efficiently transduced myeloid leukemic cell lines but gave poor results in fresh AML samples. In contrast, the AdZ.F(pK7) adenovirus containing a modified fiber protein transduced all AML samples in primary culture at relatively low virus particle concentration, with a gene transfer efficiency reaching 90-100% of the cells in 20 of the 25 samples tested. We also observed long-term expression during 15 days in most samples transduced with AdZ.F(pK7), after which rapid loss of viability of AML cells in culture was observed. This long-term expression obtained with AdZ.F(pK7) could be explained by the transduction efficiency of this vector but was also related to the low proliferation rate of AML cells in primary culture.
AdZ.F results were, however, somewhat better compared with our previous experience with a recombinant adenovirus where gene expression was driven by an RSV promoter, confirming reports which have established the lower activity of the RSV compared with the CMV promoter in hematopoietic cells. 8 The only difference between AdZ.F(pK7) and AdZ.F was the addition of a string of seven lysines at the Cterminal end of the fiber protein. 17 We were able to block AdZ.F(pK7) transduction of AML blasts with heparin and with heparinase I but not neuraminidase cell treatment. However, the HL60 promyelocytic cell line was transduced slightly better with AdZ.F, and heparin did not inhibit AdZ.F(pK7) gene delivery, suggesting that in this cell line, heparan sulfates are not required for adenovirus gene delivery. Neuraminidase treatment affected AdZ.F(pK7) but not AdZ.F transduction of two samples, which showed only moderate differences of efficiency between the two vectors, suggesting that in few samples other negative charges could participate. Thus the dramatic increase in gene transfer efficiency by AdZ.F(pK7) in AML blasts seems to be mostly related to an improvement of virus attachment by binding to heparan sulfate, as previously described in other cell types, including T cells, macrophages, endothelial and smooth muscle cells. 17 It has been previously shown that AdZ.F(pK7) vector can infect cells lacking fiber receptors. In binding experiments, inhibition of AdZ.F(pK7) adsorption could be achieved only by addition of heparinase, but not chondroitinase or neuraminidase. 18 Heparan sulfateassociated receptors like FGF receptors are broadly expressed in hematopoietic cells. 25 Additionally, recent reports have found that heparan sulfates are also the receptors of adeno-associated virus type 2 and poxviruses. 26 Herpes viruses also bind to cell surface heparan during infection, and successful transduction of AML blasts has been reported with a herpes simplex vector. 27, 28 Thus, modification of the fiber protein in order to target heparan sulfates extends the tropism of adenovirus vectors.
An important limitation of retrovirus vectors is that they require dividing cells, and therefore prolonged exposure of target cells with growth factors, which can induce cell differentiation, possibly modifying cell immunogenicity. In this study, we observed that, even though adenoviruses could transduce resting cells, the absence of GM-CSF, SCF, and IL-3 resulted in poor gene transfer efficiency. Although these growth factors are strong inducers of ␣ v integrins, their improvement of gene transfer with AdZ.F(pK7) appeared to be mainly due to an improvement in cell viability which was poor in the absence of growth factors. 29 We also cannot rule out the possibility of an activation of the CMV promoter by growth factors. Furthermore, the high efficacy of AdZ.F(pK7) gene delivery allows short culture times, limiting the duration of exposures to growth factors.
A major limitation of gene therapy in hematological malignancies was, until now, the poor efficiency of currently available vectors able to transduce malignant cells. In this study, we have shown that the modified adenovirus AdZ.F(pK7) can mediate high level transduction in primary cultured AML blasts, without major cytotoxicity. This vector overcomes the low efficiency of adenoviruses in AML blasts, and retains the advantages of recombinant adenoviruses, ie easy large-scale production and storage and infection of resting cells. Therefore, AdZ.F(pK7) vector seems suitable for future gene therapy protocols in AML.
Material and methods
AML blast cells and cell lines
Fresh cells were obtained from the peripheral blood of 25 patients with AML classified according to the FrenchAmerican-British (FAB) criteria (one M0, five M1, four M2, five M4, five M5, three AML post-myelodysplastic syndromes, two AML post chronic myeloid leukemia), and with greater than 85% circulating blast cells. Blast cells were isolated by Ficoll-Hypaque sedimentation, frozen in fetal calf serum (FCS) containing 10% dimethyl sulfoxide (DMSO; Sigma Chemical, St Louis, MO, USA) and stored in liquid nitrogen before use. After thawing, monocytes were removed by plastic adherence. T and B lymphocytes were depleted by magnetic Dynabeads CD3 and CD19, respectively (Dynal, Oslo, Norway), and AML cells were maintained in liquid culture in Iscove's medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% FCS, 100 IU penicillin, 100 g/ml streptomycin, 2 mmol/l l-glutamine, 20 ng/ml human recombinant stem cell factor (SCF) (Amgen, Thousand Oaks, CA, USA), 8 ng/ml IL3 (Novartis, Basel, Switzerland), 20 ng/ml GM-CSF (Shering Plough, Levallois Perret, France), at 37°C with 5% CO 2 . Culture medium was replaced every 3 days. The K562 chronic myelogenous leukemia cell line, HL60 promyelocytic cell line, HeLa cell lines obtained from American Type Culture Collection (ATCC, Rockville, MD, USA), were maintained in RPMI-1640 supplemented with 10% FCS (Life Technologies), 100 IU penicillin, 100 g/ml streptomycin, 2 mmol/l l-glutamine. Cells were tested for mycoplasma contamination using a mycoplasma PCR ELISA kit (Boehringer, Mannheim, Germany).
Construction of adenovirus vectors
Construction and production of chimeric AdZ.F(pK7) and control vector AdZ.F have been described previously. 17 Briefly, AdZ.F containing the ␤-galactosidase gene under the control of a cytomegalovirus (CMV) promoter (GenVec, Rockville, MD, USA) was grown in human embryonic kidney (293) cells. AdZ.F(pK7) was constructed by transfection into 293 cells of a transfer plasmid comprising an E4 sequence and a modified fiber gene encoding the fiber and a string of seven lysines at the C-terminal end of the fiber that allow high-affinity binding to heparin and heparan sulfate. 293 Cells had been preincubated with the E1−, E3−, and E4− deleted AdZ.11A (GenVec), containing the ␤-galactosidase gene under the control of a CMV promoter. Recombination of the E4+ transfer plasmid with the E4 deleted vector resulted in the rescue of an E1−, E3−, E4+ vector capable of replication in 293 cells. Both AdZ.F and AdZ.F(pK7) vectors were purified by plaque purification on 293 cells. The vectors were grown in 293 cells and purified by three successive bandings on a CsCl gradient followed by dialysis into 10 mm Tris, pH 7.8, 150 mm NaCl, 10 mm MgCl 2 3% sucrose.
Gene expression assay ␤-Galactosidase activity was measured with the CellProbe Gal.Galactosidase system (Coulter, Miami, FL, USA), according to the manufacturer's recommendations. This system uses the property of fluorescein di-galactopyranoside (FDG) to be hydrolysed by galactosidase to form a nonfluorescent leaving group and fluorescein. Cells were analyzed on an EPICS XL3C flow cytometry system (Coulter). Dead cells were excluded from analysis by forward and side scatter pattern. AML cells were gated using a FITC-conjugated rat anti-human CD33 monoclonal antibody (Immunotech, Marseille, France).
Adenovirus-mediated gene transfer
Due to the difference of infectivity between the two vectors, AdZ.F or AdZ.F(pK7) transduction efficiencies were not compared using equal p.f.u. per cell, but equal numbers of physical particles per cell, so that lower p.f.u. per cell concentration of AdZ.F(pK7) than of control AdZ.F was used in all experiments. The HeLa cell line, which has been shown to express high levels of CAR was used as the control because equal physical particle comparisons between AdZ.F and AdZ.F(pK7) have been reported to give equivalent transduction of cells which express high levels of CAR.
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AML blast cells and cell lines were washed and centrifuged. AdZ.F or AdZ.F(pK7) vectors at equal physical particle doses were added to 10 6 cells of the resuspended pellet at growing doses of 1600, 4200, 8400, 16 800 virus particles per cell, corresponding to 20, 50, 100, 200 p.f.u. per cell for AdZ.F(pK7), and 75, 150, 300, 600 p.f.u. per cell for AdZ.F, respectively (after analysis of the first 10 samples, only one dose was used), and incubated at 37°C for 1 h in 500 l volume. Culture medium was then added in order to obtain a cell concentration of 10 6 /ml and incubation continued for 24 h. Cells were then washed twice in medium to remove free viral particles, resuspended in complete medium as described above, and cultured for at least 72 h after infection. In five leukemic blast samples, infection was also performed with and without growth factors (SCF, IL-3 and GM-CSF). Each transduction was performed in triplicate.
Adenovirus competition experiments and enzymatic treatment In order to determine the mechanism leading to virus attachment, 10 AML blast samples and HL60 cell line were preincubated with 1 mg/ml heparin before infection in triplicate with AdZ.F or AdZ.F (pK7). Additionally, five AML samples and samples 7 and 8 were preincubated with heparinase I and neuraminidase: cells were washed three times in phosphate-buffered saline (PBS), and incubated with 0.1 IU/ml heparinase I (Sigma Chemical) reconstituted in PBS pH 7.6 or with 0.1 IU/ml neuraminidase (Sigma Chemical) in DMEM for 1 h at 37°C in a 5% CO 2 chamber. Cells were then washed three times in PBS, and subjected to infection with AdZ.F and AdZ.F(pK7) as described above, except that incubation with vectors was stopped by washing the cells three times in PBS after 1 h.
Statistical analysis
Statistical analysis was performed using Sigma Stat 2.0 software (SPSS, Chicago, IL, USA).
